Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGTA-456 in Inherited Metabolic Disorders
NCT03406962Phase 2Completed
- Sponsor
- Magenta Therapeutics
- Start
- Feb 2018
- Primary completion
- Feb 2020
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of spanlecortemlocel in Hurler syndrome, cerebral adrenoleukodystrophy (CALD), metachromatic leukodystrophy (MLD), globoid cell leukodystrophy (GLD), sponsored by Magenta Therapeutics. Started Feb 2018; status: completed.
02
Drugs
spanlecortemlocel
03
Conditions
Hurler syndromecerebral adrenoleukodystrophy (CALD)metachromatic leukodystrophy (MLD)globoid cell leukodystrophy (GLD)
Beyond the preview
Go deeper on NCT03406962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406962.